Physician profile
Ryan A Sullivan
NPI 1174605653
$2,338.09
in general payments reported to CMS, 2019-2025
29 companies · $448 in 2025
The $448 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $372 · 2020: $104 · 2022: $243 · 2023: $667 · 2024: $505 · 2025: $448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,619.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,619.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $493.97 | 2023-2025 | Qulipta, Ubrelvy, Vraylar |
| Glaxosmithkline, LLC. | $268.41 | 2019-2025 | Trelegy Ellipta |
| Pfizer INC. | $197.64 | 2019-2025 | |
| Organogenesis INC. | $150.25 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $144.14 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $115.02 | 2019-2024 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.61 | 2019-2023 | Jardiance |
| Lilly USA, LLC | $84.99 | 2022-2024 | Jardiance, Emgality |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $84.21 | 2023-2025 | Caplyta |
| Exact Sciences Corporation | $80.63 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $80.47 | 2019-2023 | Evenity, Prolia |
| Hologic Sales and Service, LLC | $60.78 | 2024 | Aptima, Thinprep 2000 Processor |
| Astellas Pharma US INC | $47.77 | 2022-2023 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $45.31 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $43.34 | 2019-2024 | Rexulti |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $42.21 | 2023-2025 | Gardasil 9, Vaxneuvance, M-M-R II |
| Dexcom, INC. | $37.30 | 2023-2024 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $36.35 | 2022-2025 | Trintellix |
| Regeneron Healthcare Solutions, INC. | $29.35 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $25.76 | 2019-2020 | |
| Biogen, INC. | $24.05 | 2025 | Skyclarys |
| Indivior INC. | $23.26 | 2024 | Sublocade |
| Amarin Pharma, INC. | $21.96 | 2020 | |
| Tactile Systems Technology INC | $20.26 | 2023 | Flexitouch Plus, Entre Plus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.99 | 2024 | Xifaxan |
| Axsome Therapeutics, INC. | $18.35 | 2023 | Auvelity |
| Medtronic, INC. | $14.94 | 2024 | Minimed 780g |
| Sanofi-Aventis U.S. LLC | $13.88 | 2019 | |
| Novartis Pharmaceuticals Corporation | $10.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Sullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.